文献速递心脑血管急症复苏、休克与脓毒症重症综合管理与镇静镇痛

不同机械血流动力学支持装置对心源性休克或高危PCI的短期疗效与安全性:37项试验的网络荟萃分析

Short-Term Efficacy and Safety of Different Mechanical Hemodynamic Support Devices for Cardiogenic Shock or High-Risk Pci: a Network Meta-Analysis of Thirty-Seven Trials.
PubMed 文献 · Shock · 2021-01-01
一句话结论网络荟萃分析提示ECMO+IABP可能改善心源性休克或高危PCI患者短期死亡率,但证据受限于缺乏直接比较和RCT。

本研究为网络荟萃分析,纳入38项研究共11,270例心源性休克或高危PCI患者,比较药物治疗、IABP、pMCS、单纯ECMO和ECMO+IABP五种干预。以30天或院内死亡率为短期疗效指标,ECMO+IABP较pMCS和单纯ECMO显著降低死亡率(OR=1.85,95%CI 1.03-3.26;OR=1.89,95%CI 1.19-3.01),但与药物治疗和IABP相比未显示显著降低。排序概率支持ECMO+IABP可能更优。出血方面,IABP较其他侵入性干预显示出血减少趋势。结论受限于缺乏足够直接比较和RCT证据,临床应用需考虑出血及其他装置相关并发症。

要点

  • ECMO+IABP较pMCS和单纯ECMO显著降低30天或院内死亡率(OR=1.85,95%CI 1.03-3.26;OR=1.89,95%CI 1.19-3.01)。
  • ECMO+IABP与药物治疗和IABP相比死亡率无显著差异(OR=1.73,95%CI 0.97-3.82;OR=1.67,95%CI 0.98-2.89)。
  • 排序概率支持ECMO+IABP可能是改善心源性休克或高危PCI患者死亡率更合适的干预。
  • IABP较pMCS、单纯ECMO和ECMO+IABP显示出血减少趋势(OR分别为3.86、3.74、4.80)。
  • 侵入性治疗间卒中、心肌梗死、肢体缺血和溶血无差异;结论受限于缺乏直接比较和RCT证据。

适用人群与场景

  • 心源性休克或接受高危经皮冠状动脉介入治疗(HS-PCI)的患者。
  • 原文未提及具体的纳入/排除标准、急诊/ICU/院前场景或病情阶段。

诊断标准与关键阈值

  • 短期疗效判定指标为30天或院内死亡率。
  • 原文未提及诊断标准、评分界值或启动/停止阈值。

处置流程与药物剂量

  • 比较的干预包括药物治疗、IABP、pMCS、单纯ECMO和ECMO+IABP。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型为网络荟萃分析,纳入38项研究(初始筛选1,550篇,另从参考文献补充14项),共11,270例患者,来自五个干预组。
  • 主要终点30天或院内死亡率:ECMO+IABP较pMCS显著降低(OR=1.85,95%CI 1.03-3.26),较单纯ECMO显著降低(OR=1.89,95%CI 1.19-3.01)。
  • ECMO+IABP与药物治疗(OR=1.73,95%CI 0.97-3.82)和IABP(OR=1.67,95%CI 0.98-2.89)相比死亡率无显著差异。
  • 排序概率支持ECMO+IABP可能是改善死亡率更合适的干预。
  • 出血:IABP较pMCS(OR=3.86,95%CI 1.53-10.66)、单纯ECMO(OR=3.74,95%CI 1.13-13.78)和ECMO+IABP(OR=4.80,95%CI 1.61-18.53)显示出血减少趋势。
  • 卒中、心肌梗死、肢体缺血和溶血在侵入性治疗间无差异。

证据类型、等级与局限

  • 局限:缺乏足够的直接比较和随机对照试验证据;临床应用需考虑出血和其他装置相关并发症。

对床旁实践的改变

  • 对心源性休克或高危PCI患者,ECMO+IABP可能作为改善短期死亡率的选项,但证据有限,需个体化决策。
  • 选择侵入性机械循环支持时需权衡出血风险,IABP可能出血风险较低。
  • 不适用于原文未提及的人群;不能将排序概率结果等同于确定疗效。
  • 常见陷阱:缺乏RCT证据,直接比较不足,结果需谨慎解读。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

BACKGROUND: With more advanced mechanical hemodynamic support for patients with cardiogenic shock (CS) or high-risk percutaneous coronary intervention (HS-PCI), the morality rate is now significantly lower than before. While previous studies showed that intra-aortic balloon pumping (IABP) did not reduce the risk of mortality in patients with CS compared to conservative treatment, the efficacy in other mechanical circulatory support (MCS) trials was inconsistent.

OBJECTIVE: We conducted this network meta-analysis to assess the short-term efficacy and safety of different intervention measures for patients with CS or who underwent HS-PCI.

METHODS: Four online databases were searched. From the initial 1,550 articles, we screened 38 studies (an extra 14 studies from references) into this analysis, including a total of 11,270 patients from five interventions (pharmacotherapy, IABP, pMCS, ECMO alone, and ECMO+IABP).

RESULT: The short-term efficacy was determined by 30-day or in-hospital mortality. ECMO+IABP significantly reduced mortality compared with pMCS and ECMO alone (OR = 1.85, 95% CrI [1.03-3.26]; OR = 1.89, 95% CrI [1.19-3.01], respectively). ECMO+IABP did not show reduced mortality when compared with pharmacotherapy and IABP (OR = 1.73, 95% CrI [0.97-3.82]; OR = 1.67, 95% CrI [0.98-2.89], respectively). The rank probability, however, supported that ECMO+IABP might be a more suitable intervention in improving mortality for patients with CS or who underwent HS-PCI. Regarding bleeding, compared with other invasive intervention measures, IABP showed a trend of reduced bleeding (with pMCS OR = 3.86, 95% CrI [1.53-10.66]; with ECMO alone OR = 3.74, 95% CrI [1.13-13.78]; with ECMO+IABP OR = 4.80, 95% CrI [1.61-18.53]). No difference was found in stroke, myocardial infarction, limb ischemia, and hemolysis among the invasive therapies evaluated.

CONCLUSION: Following this analysis, ECMO+IABP might be a more suitable intervention measure in improving short-term mortality for patients with CS and who underwent HS-PCI. However, the result was limited by the lack of sufficient direct comparisons and evidence from randomized controlled trials. Moreover, bleeding and other device-related complications should be considered in clinical applications.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Duan J, Shi Y, Luo G, et al. Short-Term Efficacy and Safety of Different Mechanical Hemodynamic Support Devices for Cardiogenic Shock or High-Risk Pci: a Network Meta-Analysis of Thirty-Seven Trials. Shock. 2021. PMID: 33337786. doi:10.1097/SHK.0000000000001611

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。